duvortuxizumab
mAbexperimentalMulti-specific
Duvortuxizumab (INN) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2015 (NCT02454270)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDuvortuxizumab ↗
- ChEMBLCHEMBL3990037 ↗
Also known as
- duvortuxizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02743546 | Phase 1 | Aug 1, 2016 | Johnson and Johnson |
| NCT02454270 | Phase 1 | Jun 15, 2015 | Johnson and Johnson |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2015 |
1 organizations
Page 1 / 1